

variable region of an antibody that mimics an epitope of the TAA or an epitope of an antigen associated with the infectious agent, and further wherein the variable regions of the  $\alpha$  and  $\beta$  polypeptide chains of said T cell receptor are replaced by said variable regions of the antibody.

35. The method of claim 34, wherein the cytokine is selected from the group consisting of interferon- $\gamma$  and interleukin-2.

36. The method of claim 34, wherein said TAA is carcinoembryonic antigen (CEA).

37. The method of claim 34, wherein said transfected T cells are stimulated *ex vivo* to obtain an increased mass of cells. --

#### REMARKS

Claims 1-29 are cancelled without prejudice or disclaimer, and new claims 30-37 are added. The new claims are fully supported by the specification as filed. Examination on the merits is respectfully requested.

Respectfully submitted,

October 16, 2000

Date

Brian K. Lathrop  
Agent for Applicant  
Reg. No. 43,740

**FOLEY & LARDNER**

Suite 500, 3000 K Street, N.W.  
Washington, D.C. 20007-5109  
(202) 672-5300